Fagron Sa Ord (ARSUF) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and good morning, everyone. Welcome to Fagron's H1 2025 results webcast. I'm joined today by our CEO, Rafael Padilla, and our CFO, Karin De Jong. Rafael will start by discussing the company's performance and a closer look at the regional development. Karin, well done walking you through the financial results. We will open the floor for questions at the end of the session. With that, I will hand over to Rafael. Thank you, Ignacio, and good morning all. We're pleased to report strong first half with revenue reaching 476 million. This reflects 11.3% organic growth at constant exchange rates. Growth came from all the regions and segments led by LATAM, BRANZ, North America, and compounding services. Profitability grew by 12.3% to 95 million. and our margin improved to 20% support by operational excellence and synergies from acquisitions. We also continue to execute on our M&A strategy with four new acquisitions completed, Bella Corp in Australia, Unicam and Edge Trade in Serbia, and Active Pharma in the UK. Integration of our earlier acquisitions, including LSP, Pharma Product, Curfers, EuropetSafe, and GINAMA is progressing well and in line with expectations. At SHARE, during our C&D in April, we were evaluating the expansion of Anadil's Vegas facility. We are happy to confirm that the project has now been approved and will be operational during 2028. And to finalize, our guidance for the full year remains unchanged. Meet to high single-digit organic revenue growth at constant exchange rates and slight increase in profitability year-on-year. Karin will provide more details shortly. Let us now look at the regional dynamics. In EMEA, BME performed well and continues to see the benefits of our diversified geographical footprint across the region. Compounding services ...